Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting by Rachel, Musomba et al.
RESEARCH Open Access
Uptake of hepatitis B-HIV co-infection
screening and management in a resource
limited setting
Musomba Rachel1*, Castelnuovo Barbara1, Claire Murphy2, Charlene Komujuni1, Patience Nyakato1,
Ponsiano Ocama1, Mohammed Lamorde1, Philippa Easterbrook3 and Rosalind Parkes Ratanshi4
Abstract
Background: WHO hepatitis B guidelines recommend testing all new HIV patients, treating them accordingly
or providing immunization. At the Infectious Diseases Institute (IDI) following an audit done in 2012, only 46%
patients had been screened for hepatitis B with variable management plans therefore new internal guidelines
were implemented. This study describes the uptake of hepatitis B screening and management of patients
with hepatitis B and HIV con-infection after the implementation.
Methods: Data included for all HIV positive patients in care at IDI by October 2015. Data are expressed as median with
interquartile range (IQR) and percentages were compared using the chi square test. Statistical analysis was performed
using STATA version 13. The IDI laboratory upper limit of normal for alanine aminotransferase (ALT) and aspartate
aminotransferase (ASTs) was 40 IU/ml.
Results: Number of hepatitis B screening tests increased from 800 by 2012 to 1400 in 2015. By 2015 8042/8604(93.5%)
patients had been screened for hepatitis B. Overall hepatitis B positive were 359 (4.6%). 166 (81.4%) hepatitis B positives
were switched to a tenofovir (TDF) containing regimen.
Conclusion: Our study confirms the importance of screening for hepatitis B and of using ART regimens containing
tenofovir in hepatitis B co-infected patients. Whilst our program has made improvements in care still 18.6% of patients
with hepatitis B were not on tenofovir regimens, 98.1% had no hepatitis B viral loads done. Clinicians should recognize
the potential for hepatitis B in HIV positive patients and the importance of early diagnosis and treatment to ensure
optimal management of cases and follow up.
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Background
Chronic viral hepatitis is an increasing cause of mor-
bidity and mortality among HIV confected persons, in-
cluding those on ART, as persons with HIV continue to
live longer [1–3]. The consequences of coinfection in-
clude higher rates of chronicity, less spontaneous clear-
ance, accelerated fibrosis progression with increased
risk of cirrhosis and hepatocellular carcinoma, higher
liver-related mortality, and decreased treatment re-
sponse [4–6]. Other challenges with coinfection include
cross-resistance between HIV and hepatitis B drugs,
[7–9] and increased rates of hepatoxicity [10, 11].
Chronic hepatitis B virus infection affects 5–20% of
the 36 million people living with HIV worldwide, and
the burden of HIV- hepatitis B co-infection is greatest in
low and middle income countries, particularly in sub-
Saharan Africa. Globally it is estimated that 2.6 million
are HIV- hepatitis B co-infected [12]. The World Health
Organization (WHO) in an effort to prevent and control
hepatitis B Infection has developed a global action
framework with four strategic axes: 1) raising awareness,
promoting partnerships, and mobilizing resources 2)
evidence-based policy and data for action 3) prevention
of transmission 4) screening, care and treatment. These
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strategies offer a global vision for the prevention and
control of viral hepatitis [13, 14].
Uganda is highly endemic for hepatitis B infection,
with a seroprevalence for hepatitis B positivity of
around 10%, based on a national hepatitis serosurvey
in 2005 [15, 16]. As with most of Sub-Saharan Africa,
the majority of infection is acquired at birth or dur-
ing early childhood (Franco E, 2012). In 2002, Uganda
adopted a policy of providing hepatitis B vaccination
to all infants [17] . Uganda has also adopted the 2013
WHO guidelines [18] that recommend hepatitis B
testing in all HIV infected patients,and particularly
those with elevated alanine aminotransferase (ALT),
with linkage to care and treatment, and vaccination if
Hepatitis B negative. Additionally knowledge of Hepa-
titis B serostatus allows optimal selection of antiretro-
viral drug (ARV) regimen to one that includes
tenofovir plus lamivudine or emtricitabine (TDF/3TC
or FTC) to ensure additional activity against hepatitis
B [18, 19]. During the study period, the Ugandan
Ministry of Health recommendations were for imme-
diate initiation of ART for all patients with a CD4
count less than 350 cells, and less than 500 for those
with hepatitis B HIV co-infection [20].
Whilst access to HIV care is becoming widely available
in Sub-Saharan Africa, in diagnosis and treatment of
viral hepatitis co-infection there remains a big disparity
between resource rich and poor settings. Limitations
such as the availability of further investigations and
medication can be challenging in these settings to pro-
vide individualized care for more complex patients, such
as those with co-infection [21–24].
An audit conducted in September 2012 among newly
registered patients at the Infectious Diseases Institute –
a large urban HIV clinic in Kampala, Uganda showed a
low uptake of hepatitis B screening and variable manage-
ment of those diagnosed Hepatitis B positive [25]. In
response; a new specialty clinic was set up with the aim
of identifying and appropriately care for patients co-
infected with HIV and hepatitis B.
This study describes the impact on uptake of hepa-
titis B testing, assesses whether new guidelines and
the introduction of the hepatitis B specialty clinic in-
creased hepatitis B screening uptake and improved
clinical management.
Methods
Study site and development of hepatitis B clinic services
and policies
The Infectious Diseases Institute (IDI) is an HIV center
of excellence [26] located in Mulago National referral
hospital in Kampala, Uganda. IDI was one of the first
HIV care and treatment organizations in Uganda; the
IDI clinic began providing HIV care in 2002, while free
antiretroviral treatment has been provided since April
2004. In 2015 there were more than 8000 HIV infected
patients in active care.
Timescale of key activities relating to delivery of hepatitis B
testing and treatment at IDI
1. In 2010, routine hepatitis B testing was first
introduced, followed in 2012 by establishment of a
dedicated hepatitis B clinic and clinic guidelines. The
new guidelines were written by a team of three
doctors, the quality manager and approved by the
senior Physician who is also the head of the
Prevention, Care and Treatment (PCT) department.
One staff training session was conducted and the
guidelines were implemented starting 1st September
2012. The hepatitis B clinic is held every Friday,
staffed by doctors, nurses, counselors, laboratory
technician, and pharmacist.
2. IDI has an electronic patient management system
(ICEA) [27] and since the new guidelines were
introduced in 2012, an electronic alert on the system
that reminds clinicians to request hepatitis B tests
for patients who have not been screened were
further developed, the reminder prompted clinicians
to request for the test. Samples were tested for
hepatitis B using the hepatitis B surface antigen.
Those with a positive test were termed hepatitis B
positive. Routine hepatitis core antigen testing was
not available.
3. Since September 2012, in accordance with the new
IDI clinic guidelines, all newly registered HIV
patients are tested for hepatitis B surface antigen,
while those already registered in care are tested
during their routine clinic appointments. ART naive
hepatitis B positive patients are prepared to start
ART with two pre-ART counselling sessions. In
hepatitis B positive patients already on a zidovudine
(AZT) based ART regimens, zidovudine (AZT) is
substituted for tenofovir (TDF) if the viral load is
undetectable, or switched to a second line regi-
men containing tenofovir (TDF), if viral failure is
confirmed. Free hepatitis B testing and treatment
is provided, but additional investigations including
hepatitis B DNA viral load and fibro scan to help
stage liver disease and monitor response to treat-
ment; ultrasonography and alpha-fetoprotein
measurement to screen for hepatocellular carcin-
oma; and endoscopy to screen and manage varices
due to hepatitis B infection related complications
need to be paid for by the patient. However, these
are expensive and beyond the financial means of
many of our patients.
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Study population and data collection
This analysis includes all adult (≥18 years) HIV patients
in current care at IDI from January 2002 to October
2015, with censorship at lost to follow up (LFU), trans-
fer, or death. For each patient we recorded demographic,
clinical, ART status, hepatitis B status, liver function test
results, clinical management decisions regarding use of
tenofovir containing ART regimen, and clinical out-
comes (death, LFU, transfer etc). We also describe the
number of patients tested each year, and compared the
clinical characteristics and outcomes between those who
tested hepatitis B positive and negative.
Two audits were undertaken for this study; the first
was done in September 2012 and looked at newly en-
rolled patients, the second was undertaken in October
2015 following the establishment of the hepatitis B-
HIV clinic.
Statistical analysis
We describe the number of patients tested each year
and compared baseline characteristics (age, gender,
WHO stage) in hepatitis B positive and negative patients
and described the clinical outcomes in hepatitis B posi-
tive patients. Data are expressed as median with inter-
quartile range (IQR) or number and percentages as
appropriate for (CD4 count at hepatitis B test, ART sta-
tus, current ART regimen, time in days from ART start
to hepatitis B test). Proportion of hepatitis B co-infected
patients already on a TDF containing ART regimen at
the time of test are described. To show trends of for pa-
tients tested before and after guideline implementation,
we used proportion of patients tested for hepatitis B
compared to the number of patients who registered in
the period. P values were found using Cochran-
Armitage test for trend. We used an IDI laboratory
upper limit of normal for alanine aminotransferase
(ALT) and aspartate aminotransferase (ASTs) of 40 IU/
ml. We used the t test for comparison of parametric
continuous variables, Wilkinson rank sum test for non-
parametric variables and chi square and fisher’s exact
tests for categorical variables. Statistical analysis was
performed using STATA version 13.
Results
In the first audit, 1753 patients were reviewed. Of these
only eight hundred seven patients (46%) received hepa-
titis B testing. Twenty-nine (3.6%) of those tested were
hepatitis B positive, of which 8/29 (27.6%) were not
started on ART; of note five of those had CD4 count <
500 cells/μL. Of 21 who started ART, eighteen (62.1%)
were prescribed TDF-3TC containing regimens, three
(10.3%) on ART regimens not known to have activity
against hepatitis B. 19/29 (65.5%) patients had baseline
liver function tests (LFTs) checked. No patients had fol-
low up LFTs.
During the repeat audit in October 2015, there were
8042 (93.5%) active HIV infected patients screened for
hepatitis B at IDI. Of these,2984(37.1%) were male, with
median age 31 years (IQR: 26–35), majority in WHO
stage 3 and 4; 4608(57.3%). 7416(92.2%) were initiated
on ART and were on first line ART regimen 6930
(86.2%). There has been a marked increase in the uptake
of testing per year from 611 tests in 2010, to 909 in
2012 and now 1500 in 2015. Overall, 8042 (93.5%) of
8604 current HIV infected patients have been screened
for hepatitis B with the largest number of patients being
screened between 2014 and 2015. Figure 1 shows the
number of hepatitis B tests done each year over the last
twelve years.
The proportion of patients screened for hepatitis B
compared to the number of patients newly registered in
the clinic was higher after the implementation of the
new guidelines (2141(79.3%) of 2700 versus 5901 (28.4%)
of 20,774 before the guidelines p < 0.001).
Characteristics of HIV-infected persons with and without
hepatitis B infection as of October 2015
Table 1 shows the descriptive characteristics of 359
(4.6%) hepatitis B positive patients compared to the
7083 hepatitis B negative.
Those who were hepatitis B positive, were more likely
to be male (52.6%) versus (36.4%) (P < 0.0001) and to
have a lower median CD4 count at hepatitis B test (423
cells/μL) (IQR 269–600) versus 483 cells/μL (IQR 325–
657). In addition, hepatitis B positive had been on ART
for shorter period (days 74 (IQR 27, 399) vs (105 (IQR
28, 596) days) at the time of the hepatitis B test.
There was no difference in median age at 38 (IQR)
or in WHO stage 3 and 4 (61.3%). Three hundred
thirty-seven (93.9%) of the hepatitis B positives ever
used ART with a median time on ART seventy-four
days from hepatitis B test (IQR 27–399). Two hun-
dred fifty-four (75.4%) patients started ART before
the hepatitis B test date, eighty-one (24.1%) after the
test and two (0.5%) on the day of the test. The pro-
portion of deaths (6.5%) was higher among the hepa-
titis B positives as compared to the hepatitis B
negative population (2.3%) (p value < 0.0001).
The median time from testing positive for hepatitis B
test to death was 143 days (IQR 15–242). Hepatitis B
positive patients were on ART for shorter period prior
to testing (days 74 (IQR 27, 399) as compared to the
hepatitis B negative patients (105 (IQR 28, 596) days) at
the time of the hepatitis B test. Hepatitis B positive had
lower CD4 count: 423 cells/μL, (IQR: 269–600) com-
pared to hepatitis B negative patients 483 cells/μL
(IQR:325, 657), p value < 0.0001).
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Clinical management
Figure 2. Management sequence for the 359 HIV-
hepatitis B positive persons, as of October 2015
ART management
337 (93.9%) had been started on ART, while 22 (6.1%)
had not been started not on ART at the time of the ana-
lysis. Of the 22 not on ART - most died (8, 36.4%), four
(18.2%) were lost to follow up, seven (31.8%) had been
transferred out while three (13.6%) were active in care.
One patient of those active in care had documented evi-
dence that they refused to initiate ART while two had
results returned before their scheduled return clinic
appointments date. Overall 259(76.9%) had been initi-
ated on ART prior to their hepatitis B test, and 78
(23.105%) after.
One hundred thirty-three of 337 (39.4%) patients were
already on a TDF containing ART regimen at the time of
test, 166 of 337 (49.3%) were subsequently switched to
TDF within median of 3.7 months (IQR 1.8–6.3) from
hepatitis B test, and 38 (11.2%) were never switched.
The most commonly documented reason for not switch-
ing was that the viral load was 1000 copies/ml for 24
(92.3%) hepatitis B patients.
Table 1 Demographic and clinical characteristics among hepatitis B positive and negative patients
Characteristics Hepatitis B positive N = 359 Hepatitis B negative N = 7683 P value
Male gender N (%) 189 (52.6%) 2795 (36.4%) <0.0001
Median Age (IQR) in years 38 (32, 45) 39 (32, 46) 0.119
WHO stage N (%) 3&4 220 (61.3%) 4388 (57.1%) 0.156
Median CD4 count at hepatitis B test (IQR) cells/μL 423 (269, 600) 483 (325, 657) <0.0001
Ever used ART 337 (93.9%) 7079(92.1%) 0.231
Current ART regimen N (%)
First line 316 (88.0%) 6569 (85.5%) 0.101
Second line ART 20 (5.6%) 507 (6.6%)
Third line ART 1 (0.3%) 1 (0.01%)
Median time (days, IQR) from ART start to hepatitis B test 74 (27, 399) 105 (28, 596) < 0.0001
Active 289 (83.2%) 6801 (88.5%) <0.0001
Dead 23 (6.5%) 179 (2.3%)
Lost 5 (1.4%) 118 (1.5%)
Transferred out 33 (9.6%) 585 (7.7%)
Fig. 1 Number of hepatitis B tests done performed per each year in IDI from January 2002 to October 2015
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By October 2015, two hundred ninety nine (83.3%) of
359 patients were on a TDF based regimen.
Investigations and status of liver disease
Overall 285 (79.6%) hepatitis B positives had an HIV
viral load done with 253 (70.7%) of patients with viral
load VL 1000 copies/ml. Patients who never had an
HIV viral load done 74(20.4%), 24 (32.9%) patients were
active in care, 17 (23.4%) were dead, 4 (5.5%) were lost
from care while twenty eight (38.4%) had been trans-
ferred out to other health care providers.
Liver enzymes tests (ALTs) were done for 249 (69.4%)
patients with 205 (82.3%) of patients having normal ala-
nine aminotransferase levels. Patients with Aspartate
transaminase (ASTs) test done were 86 (24%) most of
which (61.6%) had results in normal ranges.
Patients with hepatitis B DNA viral loads done were
7(1.9%) while 250 (69.6%) patients had an ultra sound
scan done.
Clinical outcomes
Overall twenty three (6.5%) of the hepatitis B positives
died, of these 9(39%) were those who had never been
initiated on ART.
Discussion
Our findings show the striking impact of the introduc-
tion and implementation of a series of clinic activities to
support the provision of effective hepatitis B care in an
HIV clinic. There was a progressive increase in the up-
take of hepatitis B testing particularly over the preceding
four years 79.3%, with now almost universal testing of all
HIV infected patients at IDI. It also shows the direct
impact of knowledge of hepatitis B status on ART regi-
men choice with 299(83.3%) of 359 patients who were
identified as positive on a TDF regimen as recom-
mended in WHO guidelines [15] and consistent with
other studies in the region [28].
This scale up and response was largely achieved as a
result of results through actions taken in response to the
findings of the first audit in 2012 showing a low uptake
of testing [25]. These actions were the creation of a
hepatitis B dedicated clinic at the facility; the develop-
ment of specific guidelines; provision of, intensive train-
ing of health care worker staff on the current guidelines;
and creation of a hepatitis B dedicated clinic at the facil-
ity. Further systems like the development of electronic
alerts on the patient management systems (ICEA) [27]
to remind clinicians to request for testing on all patients
not yet tested.
Our study showed that hepatitis B occurred in
359(4.6%) patients; slightly lower than the general hepa-
titis B seroprevalence for Kampala regions (5.3%) re-
ported in the 2005 national serosurvey [16, 29, 30].
Additional reasons for the lower prevalence maybe the
impact of effective ART with TDF and 3TC/FTC con-
taining regimens which may have resulted in hepatitis B
clearance. This concurs with other data from the
multicenter AIDS cohort study showing that hepatitis
B was significantly lower in the ART era than in the
pre-ART (IRR, 0.2 [CI, 0.1 to 0.4]), and that effective
ART is associated with lower incidence of hepatitis B
infection [31, 32].
Analysis of our study population showed that there
were more deaths 23 (6.5%) among the hepatitis B posi-
tives compared to the negatives patients 179 (2.3%, p
Fig. 2 Summarizes the management sequence for the 359 HIV infected persons identified as hepatitis B positive, as of October 2015
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value <0.0001). (Table 1) These results are similar to
findings from other studies. [2, 3, 33–36].
Further investigations and management of hepatitis B
patients is still a challenge. IDI has access to hepatitis B,
hepatitis C and E testing only. Further investigations that
would be standard in resource rich settings are not avail-
able. Additional tests including liver function tests and
ultra sound scans for hepatitis B patients were not done
for all the patients. Only 1.9% of patients were able to
have a hepatitis B DNA viral load. In Uganda generally
extensive medical investigations are expensive and be-
yond the financial means of IDI and many of the pa-
tients. In our settings, diagnosing chronic liver disease
and hepatitis infection is currently a challenge without
external funding and availability of appropriate diagnos-
tic investigations. There are also limited drug combina-
tions for those with drug resistance and for more
complex patients, such as those with co-infection.
Conclusion
Clinicians should recognize the potential for hepatitis B
in HIV positive patients and the importance of early
diagnosis and treatment to ensure optimal management
of cases and follow up. Effective prevention and treat-
ment of hepatitis B virus infection is an important public
health priority with effective ART being associated with
lower incidence of hepatitis B infection.
The Ugandan government is making progress in pri-
oritizing hepatitis B screening. We advocate for further
budgetary allocation for the implementation of hepatitis
B treatment, management and long term screening for
liver cancer. In the future additional funding is still re-
quired to increase management for complex patients
with HIV-hepatitis B co-infection and its complications.
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